Aims/hypothesis Reduced beta cell mass due to increased beta cell apoptosis is a key defect in type 2 diabetes. Islet amyloid, formed by the aggregation of human islet amyloid polypeptide (hIAPP), contributes to beta cell death in type 2 diabetes and in islet grafts in patients with type 1 diabetes. In this study, we used human islets and hIAPP-expressing mouse islets with beta cell Casp8 deletion to (1) investigate the role of caspase-8 in amyloid-induced beta cell apoptosis and (2) test whether caspase-8 inhibition protects beta cells from amyloid toxicity. Methods Human islet cells were cultured with hIAPP alone, or with caspase-8, Fas or amyloid inhibitors. Human islets and wild-type or hIAPP-expressing mouse islets with or without caspase-8 expression (generated using a Cre/loxP system) were cultured to form amyloid. Caspase-8 and -3 activation, Fas and FLICE inhibitory protein (FLIP) expression, islet beta cell and amyloid area, IL-1β levels, and the beta:alpha cell ratio were assessed. Results hIAPP treatment induced activation of caspase-8 and -3 in islet beta cells (via Fas upregulation), resulting in apoptosis, which was markedly reduced by blocking caspase-8, Fas or amyloid. Amyloid formation in cultured human and hIAPP-expressing mouse islets induced caspase-8 activation, which was associated with Fas upregulation and elevated islet IL-1β levels. hIAPP-expressing mouse islets with Casp8 deletion had comparable amyloid, IL-1β and Fas levels with those expressing hIAPP and Casp8, but markedly lower beta cell apoptosis, higher beta:alpha cell ratio, greater beta cell area, and enhanced beta cell function. Conclusions/interpretation Beta cell Fas upregulation by endogenously produced and exogenously applied hIAPP aggregates promotes caspase-8 activation, resulting in beta cell apoptosis. The prevention of amyloid-induced caspase-8 activation enhances beta cell survival and function in islets. 
Introduction
Reduced beta cell mass resulting from increased beta cell apoptosis is a key defect in type 2 diabetes [1, 2] . Islet amyloid formation in patients with type 2 diabetes contributes to progressive beta cell death [3] [4] [5] . Unlike in type 2 diabetes, amyloid forms rapidly in cultured [6] [7] [8] and transplanted human islets [9, 10] , and this is associated with beta cell dysfunction and death in vitro [6] [7] [8] , and with islet graft failure leading to recurrence of hyperglycaemia in animal models of type 1 diabetes [10] [11] [12] . Moreover, amyloid deposition associated with reduced beta cell mass has been reported in islet grafts in patients with type 1 diabetes [13, 14] . Thus islet amyloid, in addition to its role in the pathogenesis of type 2 diabetes, also contributes to islet graft failure in patients with type 1 diabetes.
Islet amyloid polypeptide (amylin), the major component of islet amyloid, is a neuroendocrine hormone that is co-localised and co-secreted with insulin from beta cells in response to beta cell secretagogues [15] . Three major factors contribute to human islet amyloid polypeptide (hIAPP) aggregation in type 2 diabetes: (1) presence of an amyloidogenic sequence in the hIAPP molecule [4] ; (2) elevated beta cell production and secretion of hIAPP due to increased insulin demand [16, 17] ; and (3) impaired prohIAPP processing and/or trafficking due to beta cell dysfunction [17] [18] [19] . Impaired clearance of secreted hIAPP because of disrupted blood vessels in isolated islets may also potentiate amyloid formation. Islet amyloid is typically found extracellular, adjacent to beta cells [6-8, 13, 20, 21] , but intracellular hIAPP aggregates also form in humans and transgenic rodent models [9, 13, 18, 21] . Small hIAPP aggregates appear to be the major mediators of beta cell death [3, 4, 22] .
In vitro studies have suggested various mechanisms for amyloid-induced beta cell death, including: the formation of non-selective ion-channel-like structures [23] ; interaction of (pro)hIAPP with components of beta cell membranes (e.g. heparan sulphate proteoglycans) [24] ; inducing endoplasmic reticulum stress [25] and oxidative stress [26] ; and disruption of the endoplasmic reticulum-associated degradation (ERAD)/ubiquitin/proteasome system [27] and autophagy/ lysosomal pathway [28] . Although several mechanisms, at least in vitro, are involved in hIAPP-induced beta cell apoptosis, some of these may share the same apoptotic signalling pathways.
Fas-mediated apoptosis has been implicated in beta cell death in type 2 diabetes [29, 30] . This pathway is initiated by interaction between the cell death receptor Fas (CD95/APO-1) and the Fas ligand (FasL/CD95L), which recruits caspase-8 (FLICE) to the death-inducing signalling complex (DISC) through interaction with the Fas-associated death domain adaptor protein. Cleaved (active) caspase-8 in turn activates downstream caspases, mainly caspase-3 [31] . Moreover, caspase-8 can indirectly activate caspase-9, the key enzyme in the cytochrome c (mitochondrial) apoptotic pathway, by its cleavage of BH3 interacting domain, which in turn evokes release of cytochrome c from mitochondria [32] . The major endogenous regulator of Fas-mediated apoptosis is the cellular FLICE inhibitory protein (FLIP), which prevents cleavage of procaspase-8 and subsequent apoptotic signals by its recruitment and cleavage in the DISC instead of procaspase-8 [31] .
Islet beta cells constitutively express FasL but do not normally express Fas at detectable levels [7, 29] . However, exposure to metabolic stress such as elevated glucose [29] , fatty acids [33] , leptin [34] or cytokines (e.g. IL-1β) [30, 35] induces beta cell Fas upregulation. We recently showed that amyloid formation in human and hIAPP transgenic mouse islets induces Fas upregulation in beta cells [7] . In this study, we used primary beta cells and human islets to examine whether amyloid-induced Fas upregulation in islet beta cells can promote activation of caspase-8, the key enzyme in the Fas-mediated apoptotic pathway. We also generated a mouse model with beta cell specific hIAPP expression and Casp8 deletion, to test whether blockade of caspase-8 can protect beta cells from the hIAPP aggregates formed in islets.
Methods
Human islet isolation and culture Human islets isolated from cadaveric pancreatic donors (36-54 years old) were provided by the Ike Barber Human Islet Transplant Laboratory (Vancouver, BC, Canada) in accordance with approved procedures and guidelines of the Clinical Research Ethics Board of the University of British Columbia. Hand-picked human islets (purity >90%, dithizone staining) were cultured in CMRL (Mediatech, Herndon, VA, USA) supplemented with 11.1 mmol/l glucose, 10% (vol./vol.) FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 50 μg/ml gentamicin. Islets were cultured in a humidified 5% CO 2 /95% air incubator (37°C, 7 days) and the medium was replaced every 2 days.
Animal models Transgenic hemizygous C57BL/6 mice with beta cell hIAPP expression (hIAPP +/− ) were kindly provided by S. Kahn (University of Washington, Seattle, WA, USA) and maintained by cross-breeding with DBA/2J mice (Jackson Laboratory, Bar Harbor, ME, USA). Male hIAPP +/− mice on a high-fat diet form islet amyloid and develop amyloid-associated diabetes in about 1 year [20] , whereas isolated islets from hIAPP +/− mice form amyloid within days during culture with elevated glucose [7, 19, 36] . Mice with beta cell-specific Casp8 deletion (RIPcre + Casp8 fl/fl ) were generated from Casp8 fl/fl mice [37] using the Cre/loxP recombinase system [38] and maintained by inter-breeding RIPcre + Casp8 fl/+ mice. Homozygous mice have agedependent (8-12 months) defects in beta cell mass in the presence of enhanced insulin secretion [38] . 
Casp8
+/+ mice. The presence of the hIAPP transgene [39] , insulin-cre transgene [40] and disrupted caspase-8 gene [37] was determined. The first generation of these offspring (10-28 weeks) was used for studies. Animals were fed mouse chow containing 9% (wt/wt) fat (Purina 5021; LabDiet, Richmond, IN, USA). Animals were cared for in accordance with the Guidelines and Principles of Laboratory Animal Care, and the standard procedures established by the Canadian Council on Animal Care and the University of British Columbia's Animal Policy and Welfare Committee.
Mouse islet isolation Mice were anaesthetised with tribromoethanol (0.25 mg/g body weight, i.p.) and killed by cervical dislocation. Ice-cold collagenase (1,000 U/ml, type XI; Sigma-Aldrich, Oakville, ON, Canada) in 2 ml calcium-free Hanks' buffer was injected via the common bile duct. Pancreases were removed and incubated for 14 min with additional 2 ml collagenase (1,000 U/ml in Hanks' buffer) in a water bath at 37°C, followed by gentle shaking for 2 min. Digestion was stopped by adding ice-cold Hanks' buffer containing 1 mmol/l CaCl 2 . Digested tissues were rinsed, centrifuged (250 g, 30 s, 4°C) and resuspended in the same solution, then filtered through a 70 μm mesh cell strainer (BD Biosciences, Oakville, ON, Canada) into Ham's-F10 (Invitrogen, Burlington, ON, Canada). To allow recovery, hand-picked islets (purity >95%) were cultured overnight in Ham's-F10 supplemented with 10 mmol/l glucose, 0.5% (wt/vol.) BSA and antibiotics as detailed for human islets, and then cultured for 7 days in Ham's-F10 with 16.7 mmol/l glucose.
Islet dissociation, culture and treatments Human or mouse islets were dissociated as described [41] and cultured in poly-Llysine-coated 8-well chamber slides in CMRL (human) or Ham's-F10 (mouse) with 5.5 and 10 mmol/l glucose, respectively. Lyophilised hIAPP and rat islet amyloid polypeptide (rIAPP) aliquots were prepared from synthetic peptides (1-37 aa; Bachem, Torrance, CA, USA) as before [41] , dissolved fresh in culture medium and added to islet cells at a final concentration of 10 μmol/l. The amyloid inhibitor Congo red (Sigma; dissolved in dimethyl sulfoxide), the caspase-8 inhibitor (z-LETD-FMK; Bachem) or the Fas antagonist (Kp7-6; EMD Chemicals, Gibbstown, NJ, USA) were prepared in culture medium at final concentrations of 25 μmol/l, 100 μmol/l and 10 mmol/l, respectively, and added to cells 1 h before hIAPP treatment. ) mouse islet cells treated with hIAPP for 8 or 24 h, respectively. Scale bar= 50 μm. Quantifications represent a minimum of ten microscopic fields each containing 100 to 150 islet cells. Results are expressed as means ± SEM of three independent studies performed in triplicate; *p<0.05 by one-way ANOVA (Jackson Laboratories, West Grove, PA, USA) and Alexa 488-conjugated anti-rabbit or anti-mouse (Molecular Probes, Eugene, OR, USA), and counterstained with the nuclear dye DAPI (blue; Vector Laboratories) for quantification studies or with 7-aminoactinomycin D (red; Molecular Probes). For insulin and A11 staining, Alexa 488-conjugated anti-guinea pig (Molecular Probes) and Texas red-conjugated anti-rabbit (Jackson) were used as secondary antibodies, respectively. For TUNEL staining, after immunolabelling for insulin, islet sections (or cells) were incubated (30 min, 37°C) with TUNEL reaction mixture (1:20; Roche Diagnostics, Laval, QC, Canada) and for amyloid staining with 0.5% (wt/vol.) thioflavin S solution (5 min, room temperature) (Sigma).
Islet insulin and hIAPP content and release Mouse islets (25 per condition) were pre-incubated (1 h, 37°C) in KRB buffer containing 10 mmol/l HEPES (pH 7.4), 0.25% BSA (wt/vol.) and 1.67 mmol/l glucose, followed by 1 h incubation in KRB containing 1.67 mmol/l glucose (basal insulin release) and another hour in KRB containing 16.7 mmol/l glucose (stimulated insulin release). Islets were lysed in 100 μl of 1 mol/l acetic acid/0.1% BSA (10 min, 100°C). Insulin levels were measured by a mouse-specific insulin ELISA kit (Alpco Diagnostics, Salem, NH, USA). Islet hIAPP content and release were assessed by a human amylin (total) ELISA kit (EZHAT-51K; EMD Millipore, Billerica, MA, USA). All values were normalised to islet protein levels (Pierce/ Thermo Scientific, Rockford, IL, USA).
Results
Exposure to exogenous hIAPP induces caspase-8 activation in human islet beta cells, which is associated with Fas upregulation and precedes caspase-3 activation and apoptosis Human islet cells were cultured in normal glucose with or without synthetic hIAPP or non-fibrillogenic rIAPP at different time points (4-24 h). Non-treated and rIAPP-treated islet cells had very low numbers of beta cells positive for active caspase-8 ( Treatment with hIAPP induced caspase-8 activation in islet beta cells in a time-dependent manner. The maximum number of beta cells positive for active caspase-8 was detectable by immunolabelling between 8 and 12 h after exposure to hIAPP (Fig. 1a) . The time point of caspase-8 activation (8-12 h) correlated with that of Fas upregulation (8-12 h), and preceded caspase-3 activation (16 h) and beta cell apoptosis (24 h) in hIAPP-treated islet beta cells (Fig. 1b-d, ESM  Fig. 1b) .
Blocking hIAPP-mediated caspase-8 activation by amyloid, caspase-8 or Fas inhibitors markedly reduces the beta cell apoptosis induced by the aggregation of exogenously applied hIAPP To identify the mechanisms underlying amyloidinduced caspase-8 activation, we tested the effects of the amyloid inhibitor Congo red, the Fas antagonist and the caspase-8 inhibitor on hIAPP-treated human islet beta cells. The amyloid-binding dye Congo red significantly reduced the number of active caspase-8 and apoptotic beta cells in hIAPPtreated cells (Fig. 2a-c) . Similarly, blockade of Fas (induced by hIAPP) with a Fas antagonist and inhibition of caspase-8 both markedly lowered the number of active caspase-8-positive and apoptotic beta cells in hIAPP-treated islet cells (Fig. 2a-c) . Basal death in untreated islet beta cells was comparable with that in cells treated with Congo red alone, but was slightly lower in those treated with the Fas antagonist or caspase-8 inhibitor alone (Fig. 2c) . Finally, hIAPP-induced beta cell apoptosis was markedly lower in islet cells from RIPcre + Casp8 fl/fl mice lacking caspase-8 than in wild-type mice that expressed caspase-8 (Fig. 2d, e) .
Amyloid formation in human islets during culture induces caspase-8 activation and beta cell death, which is associated with Fas upregulation We examined whether the formation of biosynthetic hIAPP aggregates in human islets during culture can induce caspase-8 activation in beta cells. Isolated human islets from six donors were cultured for 7 days in elevated glucose to potentiate amyloid formation. Thioflavin S (amyloid)-positive islets were not detectable in freshly isolated islets from five of six donors, but small amyloid-positive areas were detectable in about 1% of islets from one donor (Fig. 3a-c) . Islet culture resulted in progressive amyloid formation in all human islet preparations. Similarly, oligomer (A11)-positive islets were detectable in cultured islets from all donors (Fig. 3a, d) . Importantly, amyloid formation in cultured human islets was associated with caspase-8 activation in beta cells. Furthermore, thioflavin S-or oligomer (A11)-positive areas in islets closely correlated with active caspase- 8-positive beta cell areas, both of which were associated with increased beta cell apoptosis (Fig. 3a, e) and reduced islet beta cell area (Fig. 3a, f) .
The deletion of Casp8 in hIAPP-expressing mouse islet beta cells markedly reduces apoptosis induced by the aggregation of biosynthetic hIAPP during culture We generated a mouse model with beta cell-specific hIAPP expression and Casp8 deletion (Fig. 4) , to test whether blockade of caspase-8 activation can protect beta cells from amyloid toxicity in an ex vivo model of human islet amyloid formation. During 7 days of culture, hIAPP-expressing mouse islets formed amyloid, which was detectable by insulin/thioflavin S and insulin/oligomer (A11) immunolabelling (Figs 4c, 5a) . Cultured islets from hIAPP-expressing mice with or without Casp8 deletion had comparable levels of amyloid formation, hIAPP content and release (Figs 4c, 5c-g ).
Similarly to human islets, the aggregation of biosynthetic hIAPP in transgenic mouse islets during culture induced activation of caspase-8 (Fig. 5a, b) . A few active caspase-8-positive beta cells were present in cultured islets from wildtype mice expressing caspase-8, but such cells were not detectable in wild-type or hIAPP-expressing islets with beta cell Casp8 deletion (Fig. 5a) . Also, a small number of active caspase-8-positive non-beta cells were present in all genotypes. Amyloid formation and amyloid-induced Fas upregulation were associated with elevated islet IL-1β immunoreactivity in cultured hIAPP-expressing mouse islets with and without Casp8 deletion (Fig. 6a, b) . There was no detectable difference between FLIP levels in islet lysates from hIAPP-expressing and wild-type mice (Fig. 6c) . Despite similar islet IL-1β and beta cell Fas levels, hIAPP-expressing mouse islets lacking caspase-8 had significantly lower rates of beta cell apoptosis during culture than islets expressing hIAPP and caspase-8 (Fig. 7a, b) , resulting in higher beta:alpha cell ratios and islet beta cell areas in those islets (Fig. 7d, e) . Finally, the beta cell proliferation rate was not significantly different in the four genotypes (Fig. 7c) .
Cultured hIAPP-expressing mouse islets with Casp8 deletion have enhanced beta cell function compared with those expressing Casp8 Increased beta cell apoptosis in cultured islets from hIAPP-expressing mice was associated with reduced insulin response to elevated glucose (stimulation index) and reduced insulin content compared with wild-type littermates (Fig. 8) .
The stimulation index was 32% higher in cultured islets from hIAPP-expressing mice lacking caspase-8 than in islets expressing hIAPP and caspase-8, a finding that correlated with the higher (36%) insulin content in those islets (Fig. 8) . Cultured islets from mice with Casp8 deletion and without hIAPP expression had a greater (15%) insulin response to elevated glucose and higher (20%) insulin content than their wild-type littermates. However, this increase was not as profound as the difference observed between hIAPP-expressing mice lacking or expressing caspase-8, suggesting that the deletion of Casp8 improves the beta cell dysfunction caused by amyloid formation in hIAPP-expressing mouse islets during culture.
Discussion
We recently showed that hIAPP aggregates induce Fas expression in islet beta cells [7] , which do not normally express Fas at detectable levels [7, 29] . In the present study, using human islet beta cells and two ex vivo models of human islet amyloid formation, we provide direct evidence that amyloidinduced Fas upregulation in islet beta cells can promote activation of caspase-8, the key mediator of Fas apoptotic signalling, thereby initiating apoptosis. We also show that the deletion of Casp8 protects islet beta cells from the cytotoxic effects of biosynthetic hIAPP aggregates formed in islets.
In human islet beta cells (but not alpha cells), aggregates of exogenously applied hIAPP induced activation of caspase-8 and -3, resulting in apoptosis, a process that was prevented by amyloid, caspase-8 or Fas inhibitors. Caspase-8 activation preceded caspase-3 activation and apoptosis, and followed Fas upregulation. These findings suggest that Fas upregulation induced by hIAPP aggregates promotes interaction between Fas and FasL on neighbouring cells (beta cells, other islet or non-islet cells), thereby inducing caspase-8 activation. Consistent with our findings in human islet beta cells, a previous in vitro study showed that synthetic hIAPP induces caspase-8 activation in rodent beta cells [42] . Interestingly, aggregates of amyloid beta peptide were also shown to induce caspase-8 activation and apoptosis in neural cells, probably via the Fas-mediated apoptotic pathway [43] . Moreover, active caspase-8 and Fas-positive cells have been reported in the brain in Alzheimer's disease [44, 45] . Thus, it seems likely that hIAPP aggregates in type 2 diabetes and amyloid beta aggregates in Alzheimer's disease share the same apoptotic signalling pathway(s). The formation of biosynthetic hIAPP aggregates in human and hIAPP-expressing mouse islets during culture was associated with caspase-8 activation in beta cells, leading to increased beta cell apoptosis and reduced beta cell mass. Interestingly, despite comparable levels of amyloid, IL-1β and Fas in cultured hIAPP-expressing mouse islets with or without caspase-8 expression, islets lacking caspase-8 had markedly lower beta cell apoptosis, a higher beta:alpha cell ratio and a greater islet beta cell area than islets expressing caspase-8. Moreover, deletion of Casp8 in hIAPP-expressing mouse islets enhanced beta cell function, suggesting that the inhibition of caspase-8 can reduce the beta cell toxicity and improve the beta cell dysfunction mediated by biosynthetic hIAPP aggregates.
The majority of islets with amyloid formation were positive for IL-1β, Fas and caspase-8 immunoreactivity, whereas islets with no detectable amyloid formation had very low levels of all three, suggesting that amyloid may induce Fas upregulation and caspase-8 activation by promoting IL-1β release in islets. In support of this, hIAPP aggregates have been shown to promote maturation of proIL-1β to IL-1β via activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome [46, 47] . In addition, we recently showed that the inhibition of amyloid formation reduces islet IL-1β levels and Fas upregulation [7] . The cell source(s) of IL-1β in amyloid-positive islets could be beta cells, non-beta or nonislet cells (e.g. macrophages). Both macrophage-positive and macrophage-negative islet areas have been reported in hIAPP transgenic mouse islets [46] . It seems therefore that macrophages are the major, but possibly not the only source of amyloid-induced IL-1β production in islets. Taken together, these findings suggest that amyloid formation may contribute to islet inflammation in patients with type 2 diabetes [48] .
The balance between caspase-8 and its cellular regulator FLIP can switch Fas-mediated signalling to apoptosis or proliferation [49, 50] . This raises the possibility that hIAPP aggregates, like elevated glucose, may reduce beta cell FLIP levels, thereby switching Fas signalling towards apoptosis. Although we did not detect any significant difference between FLIP protein levels in lysates from 7-day islet cultures from hIAPP-expressing and wild-type mice, it is possible that potential effects of hIAPP aggregates on beta cell FLIP levels were masked in our experimental model for the following reasons: (1) elevated glucose (used to potentiate amyloid formation) can increase FLIP levels in wild-type and hIAPPexpressing mouse islets; and (2) FLIP protein levels were measured in lysates from islet cultures that contained amyloid-positive and -negative islets.
In summary, our studies show that beta cell Fas upregulation induced by hIAPP aggregates is probably mediated via release of IL-1β from islets and promotes Fas and FasL interaction, thereby initiating Fas-mediated apoptosis. We also show that deletion of Casp8 protects islet beta cells from amyloid toxicity, suggesting that caspase-8 plays a significant role in amyloid-induced beta cell apoptosis.
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